Major acquisition still on the table for Pfizer in 2015
This article was originally published in Scrip
Pfizer "has the capability of undertaking other deals independent of size," CEO Ian Read stated during the company's first quarter results presentation. The US pharma major, which announced the acquisition of Hospira and its biosimilar portfolio for $17bn in February, still has plenty of cash to spend, having walked away from the $100bn-plus buy-out of an unwilling AstraZeneca last year. It is "agnostic" to the size of any acquisition as long as it "moved the needle" and created value for shareholders, added Mr Read.